[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Keymed Biosciences Co.Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":547},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,42,65,86,107,130,155,177,198,219,239,260,281,301,322,343,366,386,406,425,447,467,489,509,529],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100632891","phase-2-a-study-of-cm512-in-patients-with-chronic-rhinosinusitis-with-nasal-polyposis-nezha-2-100632891",false,"NCT07519577","A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-2）","An Open-Label, Single-Arm, Multicenter, Extension Study to Evaluate the Safety and Efficacy of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis","Inclusion Criteria:\n\n* Participated in the clinical study of CM512 in patients with Chronic Rhinosinusitis with Nasal Polyposis (Study No. of CM512-102101) .\n\nExclusion Criteria:\n\n* Not enough washing out period for previous therapy, e.g., less than 10 weeks or 5 half-lives (whichever is longer) for Interleukin (IL)-4 receptor alpha subunit antagonists, less than 8 weeks or 5 half-lives for biologic therapy\u002Fsystemic immunosuppressant, less than 6 months for sinus surgery (including polypectomy).With malignant or benign tumor of nasal cavity.\n* Administration of a live attenuated vaccine within 30 days prior to baseline or planning to receive one during the study period.","ALL","18 Years","75 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This is an open-label, single-arm, multicenter, extension study to evaluate the safety and efficacy of CM512 in patients With Chronic Rhinosinusitis with Nasal Polyposis",[28],"Chronic Rhinosinusitis With Nasal Polyposis","NOT_YET_RECRUITING","2026-06-26",{"date":32,"type":33},"2026-06-30","ACTUAL",{"date":35,"type":22},"2026-05-31",{"date":37,"type":22},"2028-05-31",{"name":39,"class":40},"Keymed Biosciences Co.Ltd","INDUSTRY",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":41},"100594464","phase-1-study-of-cm518d1-in-patients-with-advanced-solid-tumors-100594464","NCT07019779","Study of CM518D1 in Patients With Advanced Solid Tumors","A Multicenter, Open-Label, Phase I\u002FII Clinical Study to Evaluate CM518D1 in the Treatment of Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n* 1\\. Male or female ≥ 18 and ≤75 years of age.\n* 2\\. Subjects with histologically or cytologically confirmed advanced solid tumors.\n* 3\\. At least one measurable lesion according to RECIST v1.1.\n* 4\\. Expected survival time ≥ 3 months as judged by the Investigator.\n\nExclusion Criteria:\n\n* 1\\. Subjects who have received any chemotherapy or any drug therapy for antitumor treatment including monoclonal antibodies, targeted therapy, radioimmunoconjugates, or Antibody-Drug Conjugates(ADCs), or any investigational product therapy for anti-tumor therapy within 28 days prior to the first dose or within 5 half-lives (whichever is shorter).\n* 2\\. Subjects who have received major surgery within 28 days prior to the first dose.\n* 3\\. Subjects who have received radiotherapy within 21 days prior to the first dose.\n* 4\\. Subjects who have received systemic glucocorticoid therapy (more than 10 mg of prednisone or equivalent daily) or other forms of immunosuppressive therapy within 7 days prior to the first dose.\n* 5\\. Subjects who have received any CDH17-targeted therapy.\n* 6\\. History of other malignancies within 5 years prior to the first dose, excluding cured basal or squamous cell carcinoma of skin, carcinoma cervix in situ, or breast ductal carcinoma in situ.\n* 7\\. Hypersensitivity to the investigational drug or its excipients.\n* 8\\. Pregnant or lactating female patients.",{"count":50,"type":22},434,[52,25],"PHASE1","This is an interventional study to assess the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of CM518D1 in patients with advanced solid tumors.",[55],"Advanced Solid Tumors","RECRUITING","2026-06-11",{"date":59,"type":33},"2026-06-15",{"date":61,"type":33},"2025-06-27",{"date":63,"type":22},"2029-12-31",{"name":39,"class":40},{"id":66,"slug":67,"hasResults":12,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":72,"targetDuration":4,"studyType":23,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":41},"100643042","phase-1-cm336-for-active-sjogrens-syndrome-study-100643042","NCT07642843","CM336 for Active Sjogren's Syndrome Study","Evaluation of CM336 Injection for Active Sjogren's Syndrome: an Open-Label Phase Ib Study","Inclusion Criteria:\n\n* Male or female, aged 18 to 75 years (inclusive) at the time of signing the informed consent form (ICF), and willing to comply with the study protocol requirements.\n* Body weight ≥ 45 kg at screening.\n* Voluntary compliance with the protocol requirements for permitted\u002Fprohibited concomitant therapies.\n* Definitive diagnosis of primary Sjögren's disease (SjD) according to the 2016 American College of Rheumatology (ACR)\u002FEuropean League Against Rheumatism (EULAR) classification criteria, and meeting all of the following requirements:\n\n  1. Seropositive for at least one SjD-related autoantibody.\n  2. Prior treatment with at least two systemic therapies for SjD symptoms.\n  3. Active disease at screening, defined as Clinical EULAR Sjögren's Syndrome Disease Activity Index(ClinESSDAI) ≥ 5.\n* No better therapeutic alternative available for the study participant.\n\nExclusion Criteria:\n\n* Presence of other systemic autoimmune diseases besides primary Sjögren's disease.\n* Presence of other autoimmune or inflammatory diseases.\n* Presence of any other medical condition with clinical manifestations overlapping with primary Sjögren's disease or that may interfere with result interpretation.\n* Presence of active, life-threatening, or organ-threatening SjD complications at screening.\n* History of severe allergic reactions (as judged by the investigator), or history of hypersensitivity to monoclonal antibodies or any component of CM336.\n* Presence of congenital immunodeficiency, or acquired immunodeficiency not related to the participant's autoimmune disease or its medical treatment.\n* Positive HIV antibody, positive Treponema pallidum antibody, or history of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.\n* History of tuberculosis infection.\n* Active infection requiring intravenous anti-infective treatment within 3 months before first dose of study drug, or oral anti-infective treatment within 2 weeks before first dose of study drug.\n* History of disseminated herpes zoster, or ocular\u002FCentral Nervous System herpes zoster, or systemic herpes simplex or symptomatic herpes zoster infection within 3 months before first dose of study drug.\n* Deep vein thrombosis or pulmonary embolism within 6 months before first dose of study drug.\n* History of severe cardiovascular or cerebrovascular disease, including but not limited to:\n\n  1. Unstable arrhythmia, unstable angina pectoris.\n  2. New York Heart Association (NYHA) functional class III or IV.\n  3. Uncontrolled hypertension (average systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg on two measurements despite optimal treatment).\n  4. Fridericia-corrected QT interval(QTcF) \\>450 ms for males or \\>470 ms for females\n* History of pulmonary arterial hypertension with WHO functional class II or above.\n* Presence of uncontrolled asthma or chronic obstructive pulmonary disease (COPD); uncontrolled diabetes mellitus; uncontrolled thyroid or other endocrine disorders; uncontrolled psychiatric disorders.\n* Presence of any of the following during screening:\n\n  1. Neutrophil count \\\u003C1×10⁹\u002FL, platelet count \\\u003C100×10⁹\u002FL, or hemoglobin \\\u003C80 g\u002FL (applicable only to patients without hematologic involvement).\n  2. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>2× upper limit of normal (ULN).\n  3. estimated Glomerular Filtration Rate(eGFR) \\\u003C40 mL\u002Fmin\u002F1.73m² (2021 Chronic Kidney Disease Epidemiology Collaboration formula).\n  4. Prothrombin time (PT) or activated partial thromboplastin time (APTT) \\>1.5×Upper Limit of Normal.\n* Major surgery within 3 months before screening or planned during the study period (requiring hospitalization and general anesthesia, excluding diagnostic procedures).\n* History of malignancy within 5 years before first dose of study drug (except cured basal cell carcinoma, squamous cell carcinoma of the skin, and cervical carcinoma in situ without evidence of recurrence).\n* Prior treatment with any anti-B-cell maturation antigen targeted therapy (including cell therapy or antibody therapy, etc.).\n* Receipt of prohibited medications within the corresponding timeframes.",{"count":73,"type":22},30,[52],"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CM336 in adult participants with active primary Sjogren's Syndrome.",[77],"Primary Sjögren's Syndrome (pSS)","2026-06-10",{"date":80,"type":33},"2026-06-12",{"date":82,"type":22},"2026-06",{"date":84,"type":22},"2029-02",{"name":39,"class":40},{"id":87,"slug":88,"hasResults":12,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":41},"100605722","phase-2-study-of-cm512-injection-in-subjects-with-chronic-spontaneous-urticariacsu-100605722","NCT07166211","Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)","A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of CM512 Injection in Subjects With CSU","Inclusion Criteria:\n\n* Voluntarily sign the Informed Consent Form.\n* Age ≥ 18 years old and ≤ 75 years old.\n* Patients with a diagnosis of CSU before screening visit, and the duration was ≥6 months.\n* Pruritus and wheals existed for more than 6 weeks before screening, despite regular H1-Antihistamines(AH) treatment during this period.\n* A stable dose of the second-generation H1-Antihistamines(AH) has been continuously used for at least 7 days before randomization, and the individual is willing to continue to use it stably as stipulated in the protocol during the study period.\n* Within 7 days before randomization, UAS7≥16 and ISS7 ≥8.\n\nExclusion Criteria:\n\n* Not enough washing-out period for previous therapy.\n* Planned major surgical procedure during the patient's participation in this study.\n* Has ever experienced a systemic allergic reaction or immediate allergic reaction to any biological product (including any excipients).\n* CM512 has been used before.\n* Women who are pregnant or breastfeeding. During the study period, subjects who had plans to have children, or did not agree to contraception.\n* With any medical or non-medical conditions that are not suitable for participation in this study by investigators.",{"count":94,"type":22},48,[25],"This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in subjects with CSU.",[98],"Chronic Spontaneous Urticaria (CSU)","2026-04-06",{"date":101,"type":33},"2026-04-09",{"date":103,"type":33},"2025-11-27",{"date":105,"type":22},"2027-01-14",{"name":39,"class":40},{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":114,"sex":115,"minAge":18,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":41},"100615444","phase-1-study-of-cm383-in-healthy-subjects-100615444","NCT07292688","Study of CM383 in Healthy Subjects","A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of CM383 Following Intravenous and Subcutaneous Administration in Healthy Adult Subjects","Inclusion Criteria:\n\n* Subjects age ≥ 18 years \\& ≤54 years.\n* Subjects voluntarily signed the Informed Consent Form and were able to comply with the provisions of this protocol.\n\nExclusion Criteria:\n\n* The average number of cigarettes smoked per day is greater than 5 within 3 months prior to screening.\n* Drinking heavily within 3 months prior to screening, or unable to guarantee not to drink alcohol during the research period, or positive alcohol breath testing.\n* History of drug abuse within 1 year prior to screening, or positive urine drug abuse screening.\n* Blood donation or any other form of blood loss exceeding 400 mL, or accepting blood transfusion within 12 weeks prior to screening.\n* Suspected allergy to Aβ-antibody drugs, humanized monoclonal antibody drugs and their excipients, or other biological agents, or have a history of severe allergic reactions to other drugs.\n* Severe trauma or undergo major surgery within 6 months prior to screening, or planned surgery during the research period.",true,"MALE","54 Years",{"count":73,"type":22},[52],"This study is a Phase I, single-center, randomized, open-label, parallel-controlled study, aimed at evaluating the pharmacokinetics, pharmacodynamics, immunogenicity, safety, and tolerability of a single dose of CM383 administered via intravenous infusion or subcutaneous injection in healthy male subjects.",[121],"Healthy","2026-01-22",{"date":124,"type":33},"2026-01-23",{"date":126,"type":22},"2026-01",{"date":128,"type":22},"2026-07",{"name":39,"class":40},{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":23,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},"100606433","phase-1-a-study-of-cm336-in-patients-with-relapsed-or-refractory-autoimmune-cytopenia-100606433","NCT07175493","A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia","A Phase 1\u002F2 Clinical Study of CM336 Injection in Patients With Relapsed or Refractory Autoimmune Cytopenia","Inclusion Criteria:\n\n* Voluntary provision of written informed consent and ability to comply with protocol requirements.\n* Age ≥18 years, male or female.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.\n* Confirmed diagnosis of immune thrombocytopenia (ITP), warm autoimmune hemolytic anemia (wAIHA), cold agglutinin disease (CAD), mixed autoimmune hemolytic anemia (mAIHA) or Evans Syndrome.\n* Relapsed or refractory autoimmune hemolytic anemia.\n\nExclusion Criteria:\n\n* Secondary ITP or AIHA caused by any reason. Subjects with positive autoimmune antibodies but without a clear diagnosis of any other autoimmune diseases are allowed to be enrolled.\n* Other types of AIHA or other types of cytopenia\n* History of critical diseases that, in the opinion of the investigator, may pose a risk to the safety of subjects or whose exacerbation during the study could compromise the efficacy or safety analysis of the results.\n* Received any treatment of anti-B Cell Maturation Antigen(BCMA) antibody.\n* Evaluated unsuitable to participant in this study by investigator.",{"count":138,"type":22},158,[52,25],"To evaluate the efficacy and safety of CM336 (BCMA\u002FCD3 Bispecific Antibody) in the treatment of patients with relapsed or refractory autoimmune cytopenia",[142,143,144,145],"Autoimmune Cytopenia","Immune Thrombocytopenia (ITP)","Autoimmune Hemolytic Anemia","Evans Syndrome","2025-12-09",{"date":148,"type":33},"2025-12-17",{"date":150,"type":33},"2025-11-18",{"date":152,"type":22},"2028-11-18",{"name":39,"class":40},3,{"id":156,"slug":157,"hasResults":12,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":176},"100595986","phase-2-study-evaluating-the-efficacy-and-safety-of-cm336-injection-in-the-treatment-of-light-chain-amyloidosis-100595986","NCT07039578","Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis","An Open-Label, Multi-Center, Phase II Clinical Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Relapsed or Refractory Primary Light-Chain Amyloidosis","Inclusion Criteria:\n\n* Voluntary provision of written informed consent and ability to comply with protocol requirements.\n* Age ≥18 years, any gender.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.\n* Confirmed diagnosis of primary light-chain (AL) amyloidosis.\n* Relapsed or refractory primary AL amyloidosis.\n* Measurable hematologic disease at screening (per protocol-defined criteria).\n* Involvement of ≥1 amyloid-affected organ.\n* Adequate organ function meeting all protocol-specified criteria within 3 days prior to first dose.\n\nExclusion Criteria:\n\n* Current or prior diagnosis of multiple myeloma.\n* Received anti-AL amyloidosis therapy within protocol-specified timeframe prior to first dose.\n* Clinically significant cardiovascular or cerebrovascular disease.\n* Any active or uncontrolled infection meeting protocol-defined criteria.\n* Any other condition deemed by the Investigator to preclude safe study participation.",{"count":163,"type":22},90,[25],"to Evaluate the Efficacy and Safety of CM336 (BCMA\u002FCD3 Bispecific Antibody) in Adults with Relapsed or Refractory Primary Light-Chain Amyloidosis",[167],"Primary Light-Chain Amyloidosis","2025-11-20",{"date":170,"type":33},"2025-11-26",{"date":172,"type":33},"2025-07-25",{"date":174,"type":22},"2029-07-31",{"name":39,"class":40},2,{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":23,"phases":186,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":41},"100610661","phase-2-a-long-term-safety-and-efficacy-study-evaluating-cm512-in-atopic-dermatitis-100610661","NCT07230483","A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.","An Open-Label, Multicenter Study to Evaluate Long-Term Safety and Efficacy of CM512 in Atopic Dermatitis Patients.","Inclusion Criteria:\n\n* Have the ability to understand the study and voluntarily sign a written informed consent form (ICF).\n* Subjects who have completed the week 18 evaluation in the parent study CM512-101102 or the End of Study(EOS) visit in the parent study CM512-100001.\n\nExclusion Criteria:\n\n* Not enough washing-out period for previous therapy.\n* Any other condition assessed by the investigator that makes participants unsuitable for participation in this study.",{"count":185,"type":22},246,[25],"This is an Open-label ,Multicenter Study to evaluate Long-Term Safety and Efficacy of CM512 in patients with Atopic Dermatitis who have completed treatment in parent CM512 Study.",[189],"Atopic Dermatitis (AD)","2025-11-13",{"date":192,"type":33},"2025-11-17",{"date":194,"type":22},"2025-12",{"date":196,"type":22},"2027-12",{"name":39,"class":40},{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":114,"sex":115,"minAge":18,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":23,"phases":208,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":218,"locationsCount":41},"100606434","phase-1-study-of-cm559-in-healthy-subjects-100606434","NCT07175506","Study of CM559 in Healthy Subjects","A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CM559 in Healthy Subjects With Single Ascending Dose Administration","Inclusion Criteria:\n\n* Subjects age ≥ 18 years \\& ≤60 years.\n* Subjects voluntarily signed the Informed Consent Form and were able to comply with the provisions of this protocol.\n\nExclusion Criteria:\n\n* The average number of cigarettes smoked per day is greater than 5 within 3 months prior to screening.\n* Drinking heavily within 3 months prior to screening, or unable to guarantee not to drink alcohol during the research period, or positive alcohol breath testing.\n* History of drug abuse within 1 year prior to screening, or positive urine drug abuse screening.\n* Blood donation or any other form of blood loss exceeding 400mL, or accepting blood transfusion within 12 weeks prior to screening.\n* Suspected allergy to Aβ-antibody drugs, humanized monoclonal antibody drugs and their excipients, or other biological agents, or have a history of severe allergic reactions to other drugs.\n* Severe trauma or undergo major surgery within 3 months prior to screening,or planned surgery during the research period.","60 Years",{"count":207,"type":22},40,[52],"This study is a single center, randomized, double-blind, placebo-controlled, single dose, dose escalation Phase I clinical study aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM559 administered intravenously at different doses in healthy male subjects.",[211],"Healthy Subjects","2025-09-23",{"date":214,"type":33},"2025-09-29",{"date":216,"type":22},"2025-09",{"date":82,"type":22},{"name":39,"class":40},{"id":220,"slug":221,"hasResults":12,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":226,"targetDuration":4,"studyType":23,"phases":228,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":236,"leadSponsor":238,"locationsCount":41},"100579907","phase-2-study-of-cm313-in-subject-with-iga-nephropathy-100579907","NCT06830395","Study of CM313 in Subject With IgA Nephropathy","A Phase II Clinical Study to Evaluate the Safety and Efficacy of CM313 (SC) Injection in Subjects With Primary IgA Nephropathy","Inclusion Criteria:\n\n* Able to comprehend the research study and voluntarily signing the informed consent form (ICF).\n* Renal biopsy report supporting diagnosis of primary IgAN within 8 years prior to the screening visit.\n* Estimated Glomerular Filtration Rate (eGFR) (using the Chronic Kidney Disease Epidemiology Collaboration formula) ≥ 30 mL\u002Fmin\u002F1.73 (m\\*m) at screening and baseline.\n* Prior to the baseline visit, all subjects must have received standard care treatment, including good blood pressure control and a stable treatment of a maximum recommended or maximum tolerated dose of angiotensin-converting enzyme inhibitors(ACEI) or Angiotensin receptor blocker(ARB) for at least 12 weeks.\n* 24-hour urinary protein-to-creatinine ratio (24h-UPCR) ≥ 0.75 g\u002Fg or 24-hour urinary protein excretion (24h-UPE) ≥ 1 g\u002Fd during the screening and baseline periods.\n\nExclusion Criteria:\n\n* Secondary IgAN judged by the investigator: Secondary IgAN may be associated with Henoch-Schonlein purpura, hepatic cirrhosis, coeliac disease, human immunodeficiency virus (HIV) infection, dermatitis herpetiformis, seronegative arthritis, small cell carcinoma, lymphoma, disseminated tuberculosis, obliterative bronchiolitis, inflammatory bowel disease, familial Mediterranean fever, etc.\n* Known allergy to monoclonal antibody drugs or to the excipients of CM313.\n* Presence of rapidly progressive glomerulonephritis (RPGN), defined as 50% decline in eGFR within 3 months prior to randomization and\u002For crescent formation in more than 50% of glomeruli in a renal pathological specimen.\n* Confirmed acute kidney injury (AKI) within 4 weeks prior to randomization.\n* Vaccination of any live vaccine within 30 days prior to dosing or planned vaccination during the study period.\n* History of transplantation (any solid organ transplant, including renal transplant, bone marrow transplant, etc.) or plan to undergo renal transplantation during the study.\n* History of severe recurrent or chronic infection.\n* Malignant tumor within 5 years prior to screening (except for completely cured cervix carcinoma in situ and non-skin squamous cell carcinoma metastatic or basal cell carcinoma).",{"count":227,"type":22},106,[25],"This study is divided into two parts (Part A and Part B). This study aims to evaluate the safety and efficacy of CM313 in subjects with primary Immunoglobulin A nephropathy(IgAN), while also observing its Pharmacokinetics(PK) characteristics, Pharmacokinetics(PD) effects, and immunogenicity.",[231],"IgA Nephropathy","2025-09-15",{"date":234,"type":33},"2025-09-19",{"date":216,"type":22},{"date":237,"type":22},"2028-08",{"name":39,"class":40},{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":23,"phases":248,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":257,"leadSponsor":259,"locationsCount":41},"100606875","phase-3-study-of-cm336-in-relapsed-or-refractory-multiple-myeloma-patients-100606875","NCT07181239","Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients","A Phase III, Randomized, Open-Label, Multicenter Study Comparing CM336 Monotherapy vs. Investigators Selected Standard of Care in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received ≥2 Prior Lines of Therapy","Inclusion Criteria:\n\n* The subjects voluntarily sign the informed consent form (ICF) and agree to abide by the provisions of this protocol.\n* Age ≥ 18 years old, gender is not limited.\n* Eastern Cooperative Oncology Group performance status score (ECOG) 0-2 points.\n* Patients with relapsed or refractory multiple myeloma who have received at least two lines of anti-myeloma treatment previously, and must include at least one proteasome inhibitor (PI), one immunomodulatory agent (IMiD), and one anti-Cluster of Differentiation 38(CD38) monoclonal antibody.\n* The subject has evidence of disease progression or has not achieved remission after the last line of treatment, as determined by the investigator based on the International Myeloma Working Group (2016) criteria.\n* The subject has measurable disease at the screening period, meeting at least one of the following criteria:\n\n  1. Serum M protein ≥ 5 g\u002FL;\n  2. Urinary M protein ≥ 200 mg\u002F24 h;\n  3. Serum free light chain (sFLC) ≥ 100 mg\u002FL and abnormal κ\u002F λ ratio.\n\nExclusion Criteria:\n\n* Previous receipt of any treatment targeting B-cell maturation antigen (BCMA).\n* Those who are intolerant to dexamethasone will be excluded.\n* Within 3 months prior to the first administration, they have received chimeric antigen receptor T cells (CAR-T) \u002Fchimeric antigen receptor Nature killer cell (CAR-NK) therapy.\n* Within 3 months prior to the first administration, they have received autologous stem cell transplantation; within 6 months prior to the first administration, they have received allogeneic stem cell transplantation (for subjects who have received allogeneic transplantation, they must have discontinued all immunosuppressants for ≥ 6 weeks and have no signs of graft-versus-host disease before being eligible for enrollment).",{"count":247,"type":22},280,[249],"PHASE3","The purpose of this study is to compare the efficacy between CM336 and investigator's choice Standard of Care in relapsed or refractory multiple myeloma (RRMM) patients.",[252],"Multiple Myeloma (MM)","2025-09-12",{"date":255,"type":33},"2025-09-18",{"date":216,"type":22},{"date":258,"type":22},"2030-04",{"name":39,"class":40},{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":267,"targetDuration":4,"studyType":23,"phases":269,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":41},"100593829","phase-2-study-of-cm512-injection-in-subjects-with-moderate-to-severe-asthma-100593829","NCT07011524","Study of CM512 Injection in Subjects With Moderate-to-severe Asthma","A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of CM512 Injection in Subjects With Moderate-to-severe Asthma.","Inclusion Criteria:\n\n* Able to understand and comply with procedures of the protocol, and voluntarily sign the Informed Consent Form.\n* Age ≥ 18 years old and ≤ 75 years old.\n* Body mass index (BMI) ≥ 18.0 kg\u002F(m\\*m).\n* Documented treatment with medium to high dose Inhaled Corticosteroids (ICS) in combination with asthma controller medication for at least 3 months with a stable dose ≥1 month prior to Visit 1.\n* Documented history of at least 1 severe asthma exacerbation events within 12 months, and at least one of the exacerbations should occur during the treatment of medium-to-high dose ICS.\n* Asthma Control Questionnaire-6 (ACQ-6) score ≥1.5\n\nExclusion Criteria:\n\n* Women of childbearing potential have a positive pregnancy test result during the screening period; women who are pregnant or lactating.\n* With a history of drug abuse within the past 5 years before screening visit.\n* Allergic or intolerant to CM512 injection or placebo components, or with a history of severe drug allergies or anaphylactic shock.\n* With any medical or non-medical conditions that are not suitable for participation in this study by investigators.",{"count":268,"type":22},200,[25],"This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial evaluating the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in subjects with moderate-to-severe asthma.",[272],"Asthma","2025-08-21",{"date":275,"type":33},"2025-08-28",{"date":277,"type":33},"2025-08-19",{"date":279,"type":22},"2027-07-21",{"name":39,"class":40},{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":288,"targetDuration":4,"studyType":23,"phases":289,"briefSummary":290,"conditions":291,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":41},"100588943","phase-2-study-of-cm512-in-patients-with-moderate-to-severe-atopic-dermatitis-100588943","NCT06947980","Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis","A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis","Inclusion Criteria:\n\n* Patients with a diagnosis of AD for at least 1 year according to the American Academy of Dermatology's consensus criteria prior to the screening visit meeting all of the following criteria:\n* EASI≥16 at Screening and Baseline visits;\n* Investigator's Global Assessment (IGA) score of≥3 at Screening and Baseline visits;\n\n  * 10% Body Surface Area (BSA) of AD involvement at Screening and Baseline visits;\n* Mean of weekly Pruritus Numeric Rating Scale (NRS) severity score≥4 at Baseline;\n\nExclusion Criteria:\n\n* Not enough washing-out period for previous therapy.\n* Concurrent disease\u002Fstatus which may potentially affect the efficacy\u002Fsafety judgement.\n* Organ dysfunction.\n* Pregnancy.\n* Other.",{"count":268,"type":22},[25],"A Phase 2 study designed to evaluate the efficacy and safety of CM512 in adult patients with moderate-to-severe Atopic Dermatitis (AD).",[292],"Atopic Dermatitis","2025-08-12",{"date":295,"type":33},"2025-08-17",{"date":297,"type":33},"2025-06-19",{"date":299,"type":22},"2026-11-07",{"name":39,"class":40},{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":308,"targetDuration":4,"studyType":23,"phases":310,"briefSummary":311,"conditions":312,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":41},"100576955","phase-1-study-of-cm313sc-injection-in-subjects-with-platelet-transfusion-refractoriness-100576955","NCT06792019","Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness","A Phase IB\u002FII Clinical Study to Assess the Safety and Preliminary Efficacy of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness","Inclusion Criteria:\n\n1. Thrombocytopenia dependent on platelet transfusions and diagnosed with platelet transfusion refractoriness.\n2. Presence of one or more kinds of antiplatelet antibodies.\n3. Male or female, age≥18 years.\n4. The Eastern Cooperative Oncology Group (ECOG) physical status score ≤2.\n5. Willing and able to comply with the requirements for this study and written informed consent.\n\nExclusion Criteria:\n\n1. Diagnosed with Idiopathic thrombocytopenic purpura.\n2. Platelet transfusion refractoriness caused by non-immune factors.\n3. Previously treated with the anti-CD38 monoclonal antibody.\n4. Have an allergy to humanized monoclonal antibody or any part of CM313.\n5. Pregnant or breastfeeding females, or females planning to become pregnant during the study.\n6. Any condition considered to be ineligible for the study by the investigator.",{"count":309,"type":22},110,[52,25],"This is a randomized, open-label, phase IB\u002FII clinical study to evaluate the safety and preliminary efficacy of CM313(SC) injection in patients with Platelet Transfusion Refractoriness.",[313],"Platelet Transfusion Refractoriness","2025-08-11",{"date":316,"type":33},"2025-08-15",{"date":318,"type":33},"2025-03-25",{"date":320,"type":22},"2027-11-16",{"name":39,"class":40},{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":12,"sex":17,"minAge":329,"maxAge":330,"enrollmentInfo":331,"targetDuration":4,"studyType":23,"phases":333,"briefSummary":334,"conditions":335,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":340,"leadSponsor":342,"locationsCount":41},"100601121","phase-3-a-study-of-stapokibatrt-in-children-subjects-with-atopic-dermatitis-100601121","NCT07106372","A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis","A Multi-center, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Stapokibatrt in Children With Atopic Dermatitis","Inclusion Criteria:\n\n* Voluntarily participate in the continuing study and sign the written Informed Consent Form(ICF).\n* Subjects who must complete the evaluation of Week 18 of the main study.\n* Have the ability to communicate well with the researcher and comply with the follow-up visits of the protocol.\n\nExclusion Criteria:\n\n* Planned major surgical procedure during the patient's participation in this study.\n* Any other circumstances in which the researcher deems not suitable to participate in this study.","2 Years","12 Years",{"count":332,"type":22},240,[249],"This is a multi-center, single-arm, open-label phase 3 study to evaluate the safety, efficacy, Pharmacokinetics(PK) and immunogenicity of Stapokibatrt in children with Atopic Dermatitis.",[292],"2025-08-05",{"date":338,"type":33},"2025-08-06",{"date":216,"type":22},{"date":341,"type":22},"2027-06",{"name":39,"class":40},{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":17,"minAge":350,"maxAge":351,"enrollmentInfo":352,"targetDuration":4,"studyType":23,"phases":354,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":4},"100591416","phase-2-a-study-of-cm512-in-subjects-with-moderate-to-severe-chronic-obstructive-pulmonary-disease-100591416","NCT06980142","A Study of CM512 in Subjects With Moderate-to-Severe Chronic Obstructive Pulmonary Disease","A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating CM512 Injection in Subjects With Moderate-to-Severe Chronic Obstructive Pulmonary Disease","Inclusion Criteria:\n\n* 40 to ≤ 80 years old\n\n  * BMI ≥ 18.0 kg\u002F(m\\*m)\n  * COPD diagnosis≥1 year\n  * Post-BD FEV1 ≥ 30% and \\\u003C 80%, FEV1\u002FFVC \\\u003C0.70 at screening\n  * Triple (LABA+LAMA+ICS) or dual inhaled (LABA+LAMA or LABA+ICS) COPD therapy ≥3 months prior to V1\n* 2 moderate or ≥1 severe COPD exacerbations in the prior year\n\n  * CAT ≥10 at screening\n  * Former or current smokers ≥10 pack-years\n\nExclusion Criteria:\n\n* Clinically important pulmonary disease other than COPD, as judged by the Investigator (including current or historic asthma diagnosis).\n* Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment that is not stable.\n* Treatment with oxygen of more than 15 hours per day.\n* Pregnant or breastfeeding.\n* The chest\u002Flungs with pathology that precludes the patient's ability to complete the study.","40 Years","80 Years",{"count":353,"type":22},204,[25],"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase II Study to Explore the Efficacy and Safety of CM512 Injection in Adults with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)",[357],"Chronic Obstructive Pulmonary Disease","2025-05-12",{"date":360,"type":33},"2025-05-20",{"date":362,"type":22},"2025-06-20",{"date":364,"type":22},"2028-03-17",{"name":39,"class":40},{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":12,"sex":17,"minAge":329,"maxAge":373,"enrollmentInfo":374,"targetDuration":4,"studyType":23,"phases":375,"briefSummary":376,"conditions":377,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":41},"100589575","phase-3-study-of-stapokibatrt-in-children-subjects-with-atopic-dermatitis-100589575","NCT06956196","Study of Stapokibatrt in Children Subjects With Atopic Dermatitis","A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Stapokibatrt in Children With Moderate-to-severe Atopic Dermatitis","Inclusion Criteria:\n\n* Age ≥ 2 and ≤ 11 years old.\n* Diagnosis of AD according to the American Academy of Dermatology Consensus (2014) Criteria.\n* With moderate-to-severe AD, and inadequate response to topical medications.\n\nExclusion Criteria:\n\n* Prior treatment with Stapokibart\n* Treatment with dupilumab within 13 weeks prior to the baseline visit, or treatment with anti-IgE(Immunoglobulin E) monoclonal antibody，other biological agents within 5 half-lives prior to the baseline visit .\n* Treatment with immunosuppressants\u002Fimmunomodulatory drugs, ultraviolet therapy, or systemic traditional Chinese medicine for AD within 4 weeks prior to the baseline visit.\n* Treatment with a topical corticosteroids (TCS), topical calcineurin inhibitor (TCI) or topical Phosphodiesterase-4(PDE-4) inhibitor within 1 weeks prior to the baseline visit.\n* History of atopic keratoconjunctivitis invading cornea.\n* Acute attacks of Atopic Dermatitis within 4 weeks prior to the baseline visit.\n* Planned major surgical procedure during the patient's participation in this study.","11 Years",{"count":332,"type":22},[249],"This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, Pharmacokinetics(PK), PharmacoDynamics(PD) and immunogenicity of Stapokibatrt in children with moderate-to-severe atopic dermatitis.",[292],"2025-04-30",{"date":380,"type":33},"2025-05-04",{"date":382,"type":22},"2025-05",{"date":384,"type":22},"2026-08",{"name":39,"class":40},{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":393,"targetDuration":4,"studyType":23,"phases":395,"briefSummary":396,"conditions":397,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":176},"100459541","phase-1-a-study-of-cm350-in-patients-with-advanced-solid-tumors-100459541","NCT05263960","A Study of CM350 in Patients With Advanced Solid Tumors","A Multicenter, Open Label, Phase I\u002FII Clinical Study of CM350 in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n* Patient with histologically or cytologically confirmed advanced solid tumors that is refractory to or intolerable with standard treatment, or for which no standard treatment is available.\n* hepatocellular-cancer(HCC) participants must have a Barcelona Clinic Liver Cancer (BCLC) stage of B (ineligible for liver surgery and\u002For other locoregional treatments, or disease progression after locoregional therapy) or stage C , or a China National Liver Cancer (CNLC) stage of IIb or III (ineligible for liver surgery and\u002For other locoregional treatments, or disease progression after locoregional therapy).\n* HCC participants must have a Child-Pugh score of ≤7.\n* Phase I dose escalation phase: participants must have evaluable lesions based on RECIST version 1.1.Phase I dose expansion phase and phase II: participants must have at least one measurable lesion.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\nExclusion Criteria:\n\n* Patients who have received any cytotoxic chemotherapy, radiotherapy, biological therapy (oncologic vaccines, cytokines, or growth factors for cancer control), or any other investigational anticancer drug treatment (defined as treatments without regulatory approval for any indication) within 28 days before the first dose of CM350.\n\nNote: For palliative radiotherapy to non-central nervous system lesions (total radiotherapy duration ≤14 days) to improve symptoms, a minimum washout period of 7 days before the first dose is required.\n\n* Patients who have received any immunotherapy (including but not limited to PD-1, PD-L1, anti-cytotoxic T-lymphocyte-associated antigen 4 \\[CTLA-4\\], chimeric antigen receptor T-cell \\[CAR-T\\] therapy, etc.) within 28 days or 5 half-lives (whichever is shorter) before the first dose of CM350.\n* Patients who have received targeted therapy within 28 days or 5 half-lives (whichever is shorter) before the first dose of CM350.\n* Patients who have previously received any therapy targeting GPC3, including but not limited to monoclonal antibodies, peptide vaccines, CAR-T, and bispecific antibodies.\n* Received chronic systemic corticosteroid therapy (daily intake of more than 10 mg prednisone or equivalent doses of other corticosteroids) or any other form of immunosuppressive treatment within 7 days before the first dose of CM350.\n* Known active central nervous system metastases. Note: Participants with previously treated brain metastases that have been stable for at least 14 days before the first dose (confirmed by repeat imaging at least 4 weeks apart, with the repeat imaging conducted during the screening period) may be considered for enrollment.\n* Participants with uncontrolled pleural effusion, ascites, or pericardial effusion as assessed by the investigator.\n* History of other malignancies within 5 years before the first dose of CM350, excluding cured basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, or ductal carcinoma in situ of the breast.\n* Presence of active infection at screening as assessed by the investigator.",{"count":394,"type":22},248,[52,25],"This is an open label, dose escalation and expansion Phase I\u002FII study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of CM350 in patients with advanced solid tumors.\n\nThe phase I study consists of a dose escalation phase and a dose expansion phase The safety and tolerability of CM350 and the maximum tolerated dose (MTD) (if applicable) will be evaluated in dose escalation phase.\n\nThe recommended phase 2 dose (RP2D) of CM350 will be determined in dose expansion phase.\n\nThe phase II study is to evaluate the efficacy of CM350 at the recommended phase 2 dose (RP2D) for advanced glypican-3 (GPC3)-positive solid tumors.",[398],"Advanced Solid Tumor","2025-04-29",{"date":380,"type":33},{"date":402,"type":33},"2022-04-21",{"date":404,"type":22},"2027-04",{"name":39,"class":40},{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":413,"targetDuration":4,"studyType":23,"phases":414,"briefSummary":415,"conditions":416,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":41},"100587609","phase-2-a-study-of-cm512-in-patients-with-chronic-rhinosinusitis-with-nasal-polyposis-nezha-1-100587609","NCT06930612","A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-1）","A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis","Inclusion Criteria:\n\n* with chronic rhinosinusitis with nasal polyposis (CRSwNP).\n* Nasal Polyp Score (NPS) of ≥5 with a minimum score of 2 in each nasal cavity.\n* Nasal Congestion Score of 2 or 3 at screening period, and at least 2 at baseline.\n* Contraception.\n\nExclusion Criteria:\n\n* Not enough washing out period for previous therapy, e.g., less than 10 weeks or 5 half-lives (whichever is longer) for Interleukin (IL)-4 receptor alpha subunit antagonists, less than 8 weeks or 5 half-lives for biologic therapy\u002Fsystemic immunosuppressant, less than 6 months for sinus surgery (including polypectomy).With malignant or benign tumor of nasal cavity.\n* Vaccination with live attenuated vaccine within 30 days before randomization or during the planned study period.",{"count":21,"type":22},[25],"This is a multi-center, randomized, double blind, placebo-controlled Phase II study to evaluate the efficacy and safety of CM512, and to observe the life quality of subjects, the Pharmacokinetics, Pharmacodynamics and immunogenicity of CM512 in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP).",[28],"2025-04-09",{"date":419,"type":33},"2025-04-16",{"date":421,"type":22},"2025-05-16",{"date":423,"type":22},"2026-09-16",{"name":39,"class":40},{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":12,"sex":17,"minAge":432,"maxAge":433,"enrollmentInfo":434,"targetDuration":4,"studyType":23,"phases":435,"briefSummary":436,"conditions":437,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":41},"100563703","phase-1-a-study-of-cm383-in-patients-with-alzheimers-disease-related-mild-cognitive-impairment-and-mild-alzheimers-disease-100563703","NCT06619613","A Study of CM383 in Patients With Alzheimer's Disease Related Mild Cognitive Impairment and Mild Alzheimer's Disease","A Randomized, Double-blind, Placebo-controlled and Multiple Dose Escalation Phase Ib Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CM383 in Patients With Alzheimer's Disease Related Mild Cognitive Impairment and Mild Alzheimer's Disease","Inclusion Criteria:\n\n* Voluntarily participate and have the subject and their legal guardian jointly sign the Informed Consent Form.\n* The age of the subjects is between 50 and 85 years old.\n* BMI≥19kg\u002Fm2 and ≤32.5 kg\u002Fm2, weight ≥45 kg and ≤100 kg at screening or baseline.\n\nExclusion Criteria:\n\n* Cognitive impairment of subjects due to other medical or neurological factors (other than AD)\n* History of stroke or transient ischemic attack, seizures, or other unexplained loss of consciousness within the past year\n* With any mental illness that may interfere with the cognitive assessment of the subjects.\n* With history of moderate or severe renal dysfunction.\n* With Uncontrolled stable hypertension.\n* With history of severe trauma or major surgery in the 6 months prior to the screening period, or planned surgery during the study.\n* History of malignancy within 5 years prior to screening.","50 Years","85 Years",{"count":94,"type":22},[52],"This is a randomized, double-blind, placebo-controlled and multiple dose escalation phase Ib study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM383 in patients with Alzheimer's disease related mild cognitive impairment and mild Alzheimer's disease.",[438],"Alzheimer Disease","2025-03-14",{"date":441,"type":33},"2025-03-19",{"date":443,"type":33},"2024-11-08",{"date":445,"type":22},"2026-12-30",{"name":39,"class":40},{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":454,"targetDuration":4,"studyType":23,"phases":456,"briefSummary":457,"conditions":458,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":466,"locationsCount":41},"100576940","phase-1-study-of-cm313sc-injection-in-subjects-with-relapsedrefractory-aplastic-anemia-100576940","NCT06791824","Study of CM313(SC) Injection in Subjects With Relapsed\u002FRefractory Aplastic Anemia","A Phase IB\u002FII Clinical Study to Assess the Safety, Tolerability and Preliminary Efficacy of CM313(SC) Injection in Subjects With Relapsed\u002FRefractory Aplastic Anemia","Inclusion Criteria:\n\n1. Diagnosis of idiopathic aplastic anemia.\n2. Patients must meet the requirements of relapsed\u002Frefractory aplastic anemia defined in the protocol.\n3. Male or female, age≥18 years.\n4. The Eastern Cooperative Oncology Group (ECOG) physical status score ≤2.\n5. Willing and able to comply with the requirements for this study and written informed consent.\n\nExclusion Criteria:\n\n1. The inherited bone marrow failure syndromes.\n2. Previously treated with the anti-CD38 monoclonal antibody.\n3. Have an allergy to humanized monoclonal antibody or any part of CM313.\n4. Pregnant or breastfeeding females, or females planning to become pregnant during the study.\n5. Any condition considered to be ineligible for the study by the investigator.",{"count":455,"type":22},125,[52,25],"This is a randomized, open-label, phase IB\u002FII clinical study to evaluate the safety, tolerability and preliminary efficacy of CM313(SC) injection in patients with relapsed\u002Frefractory aplastic anemia",[459],"Aplastic Anemia","2025-02-14",{"date":462,"type":33},"2025-02-18",{"date":464,"type":22},"2025-03",{"date":196,"type":22},{"name":39,"class":40},{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":474,"enrollmentInfo":475,"targetDuration":4,"studyType":23,"phases":477,"briefSummary":478,"conditions":479,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":41},"100576936","phase-2-study-of-cm313sc-injection-in-systemic-lupus-erythematosussle-100576936","NCT06791772","Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)","A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of CM313(SC) Injection in Subjects With Systemic Lupus Erythematosus","Inclusion Criteria:\n\n1. Males or females aged 18 to 65 years.\n2. Voluntarily signed the informed consent form (ICF).\n3. Patients were diagnosed with systemic lupus erythematosus(SLE) according to the diagnostic classification criteria of the European League against Rheumatism (EULAR)\u002FAmerican College of Rheumatology (ACR) in 2019.\n4. Systemic Lupus Erythematosus Disease Activity Index - 2000(SLEDAI-2K) score ≥6 during screening, and SLEDAI-2K clinical score (except for low complement and\u002For positive anti-dsDNA antibodies) ≥4 during screening and at baseline.\n5. Positive antinuclear antibody and\u002For anti-dsDNA antibody results defined in accordance with the laboratory reference value range of the Central laboratory during the screening.\n6. ≥1British Isles Lupus Assessment Group-2004 (BILAG-2004) organ system rated as A or ≥ 2 organ system rated as B, and Physician's Global Assessment(PGA) score ≥1.0 during screening.\n7. Maintain a stable standard treatment regimen for at least 30 days prior to initial dosing of the investigational product.\n\nExclusion Criteria:\n\n1. Kidney disease: Severe lupus nephritis within within 8 weeks prior to randomization.\n2. Patients with systemic lupus erythematosus(SLE) or non-SLE related central nervous system disease within 8 weeks prior to randomization.\n3. There were non-SLE inflammatory skin or joint diseases that the investigators thought might be evaluated during the screening period.\n4. History of clinically significant diseases.","65 Years",{"count":476,"type":22},150,[25],"To evaluate the efficacy and safety of CM313(SC) injection in systemic lupus erythematosus(SLE)",[480],"Systemic Lupus Erythematosus","2025-01-19",{"date":483,"type":33},"2025-01-24",{"date":485,"type":22},"2025-02",{"date":487,"type":22},"2027-02",{"name":39,"class":40},{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":495,"eligibilityCriteria":496,"healthyVolunteers":12,"sex":17,"minAge":330,"maxAge":474,"enrollmentInfo":497,"targetDuration":4,"studyType":23,"phases":498,"briefSummary":499,"conditions":500,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":41},"100556476","phase-2-study-of-stapokibart-injection-in-patients-with-allergic-rhinitis-100556476","NCT06525597","Study of Stapokibart Injection in Patients With Allergic Rhinitis","A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of Stapokibart Injection in Patients With Allergic Rhinitis","MIZAR","Inclusion Criteria:\n\n* Able to understand the study and voluntarily sign the Informed consent form.\n* Diagnosed Allergic Rhinitis according to the Criteria stated in the Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (2022, Revised Edition).\n* Subjects with asthma must be evaluated by the researcher as having a stable condition.\n* Has a positive skin prick test (SPT) or positive antigen-specific serum immunoglobulin E (IgE).\n\nExclusion Criteria:\n\n* Use of anti-interleukin 4 receptor alpha subunit (IL-4Rα) monoclonal antibody, thymic stromal lymphopoietin (TSLP) monoclonal antibody, anti-IgE monoclonal antibody, other monoclonal antibodies, or other biologics within 10 weeks or 5 half-lives (whichever is longer) prior to the screening visit.\n* Use of any investigational product within 4 weeks prior to the screening visit or planning to participate in other clinical studies during this study.\n* Forced expiratory volume in 1 second (FEV1) ≤ 50% of the predicted value during the screening\u002Frun-in period.\n* Have acute sinusitis, nasal infection, or upper respiratory tract infection at screening or within 2 weeks prior to screening.\n* Have received a live-attenuated vaccine within 12 weeks prior to randomization or planning to receive one during the study.",{"count":21,"type":22},[25],"This study is a Randomized, Double-blind, Placebo-controlled phase II clinical study evaluating the efficacy and safety of Stapokibart injection in patients with allergic rhinitis.",[501],"Allergic Rhinitis","2024-11-07",{"date":443,"type":33},{"date":505,"type":33},"2024-09-30",{"date":507,"type":22},"2025-10-30",{"name":39,"class":40},{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":516,"targetDuration":4,"studyType":23,"phases":518,"briefSummary":519,"conditions":520,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":41},"100498806","phase-2-clinical-study-of-cm338-in-the-treatment-of-immunoglobulin-a-nephropathy-100498806","NCT05775042","Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy","A Phase II Clinical Study Evaluating the Efficacy and Safety of CM338 Injection in Subjects With Immunoglobulin A Nephropathy","Inclusion Criteria:\n\n* Male or female aged 18-75.\n* Understand the nature of the study and sign the Informed Consent Form voluntarily.\n* Take effective contraception measures throughout the study period.\n\nExclusion Criteria:\n\n* Used other investigational drugs within 30 days before the first study administration.\n* With previous history of Human immunodeficiency virus(HIV) infection.\n* Treponema pallidum antibody positive in screening period.\n* May have active Mycobacterium tuberculosis infection.\n* Major surgery is planned during the study.\n* Other reasons the investigator believes that the subject is not suitable to participate in this study.",{"count":517,"type":22},70,[25],"This study is a multicenter, randomized phase II clinical study to evaluate Efficacy and safety, while observing pharmacokinetic profiles, pharmacodynamic effects, and immunogenicity of CM338 in subjects with Immunoglobulin A(IgA) nephropathy.",[231],"2024-10-14",{"date":523,"type":33},"2024-10-15",{"date":525,"type":33},"2023-05-08",{"date":527,"type":22},"2027-06-30",{"name":39,"class":40},{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":536,"targetDuration":4,"studyType":23,"phases":537,"briefSummary":538,"conditions":539,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":541,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":41},"100462266","phase-1-a-study-of-cm336-in-patients-with-relapsed-or-refractory-multiple-myeloma-100462266","NCT05299424","A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma","A Multi-center, Open-label, Phase 1\u002F2 Clinical Study of CM336 Injection in Patients With Relapsed or Refractory Multiple Myeloma","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group Performance Status (ECOG) of 0-2.\n* Patients with relapsed or refractory MM who have failed or are intolerant to all therapies with known clinical benefit; patients must have received at least 2 prior anti-myeloma therapies which must contain at least one proteasome inhibitor (PI), one immunomodulatory drug (IMiD), and one anti-CD38 monoclonal antibody (if available).\n\nExclusion Criteria:\n\n* Patients who had received BCMA-targeted therapy.\n* Patients who had received CAR-T therapy.\n* Patients who had received anti-tumor therapy within 3 weeks or 5 half-lives (whichever is shorter) prior to the first dose of CM336.",{"count":94,"type":22},[52,25],"This is a multi-center, open-label, Phase 1\u002F2 study in China to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics and immunogenicity of CM336 in patients with relapsed or refractory multiple myeloma.\n\nThis study consists of a dose escalation part (Phase 1) and a dose extension part (Phase 2 ).\n\nThe safety and tolerability of CM336 will be evaluated in Phase 1 study, as well as the maximum tolerated dose (MTD) and the recommended dose level for Phase 2 study will be determined.\n\nThe efficacy of CM336 will be evaluated in Phase 2 study.",[540],"Multiple Myeloma",{"date":523,"type":33},{"date":543,"type":33},"2022-08-09",{"date":545,"type":22},"2026-12",{"name":39,"class":40},""]